Top

Published in:

01-03-2014 | Research Article

NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis

Authors: Li-Li Liu, Mei-Fang Zhang, Ying-Hua Pan, Jing-Ping Yun, Chris Zhiyi Zhang

Published in: Tumor Biology | Issue 3/2014

Abstract

NORE1A, identified as a Ras effector, is frequently silenced in human cancers and has been implicated in tumour progression. Reports showing that NORE1A may function as a tumour suppressor have been emerging. However, to date, its expression and relevant significance in hepatocellular carcinoma (HCC) remain elusive. In this study, we examined the expression of NORE1A in HCC cell lines and a cohort of 250 HCC samples. We found that both the mRNA and the protein levels of NORE1A were noticeably downregulated in 14 fresh HCC tissues, compared to corresponding paracarcinoma tissues. Furthermore, NORE1A in tumours was decreased in 72.4 % (181/250) of HCC patients. Low NORE1A expression was significantly associated with poor differentiation (P = 0.003), advanced stage (P = 0.002), high level of serum AFP (P < 0.001), vascular invasion (P = 0.034) and incomplete involucrum (P = 0.018). Multivariate analysis revealed that NORE1A was an independent poor prognostic factor for both overall survival (hazard ratio (HR) 0.622, 95 % confidence interval (95 % CI) 0.405–0.956, P = 0.030) and recurrence-free survival (HR 0.613, 95 % CI 0.390–0.964, P = 0.034). Moreover, low NORE1A expression in advanced-stage HCC predicted disease relapse. In addition, NORE1A overexpression reduced cell viability, inhibited colony formation, and attenuated cell invasion in vitro. Further study demonstrated that NORE1A was capable of sensitising cancer cells to sorafenib-induced apoptosis via the activation of the Mst-1/Akt pathway. Collectively, our data suggest that NORE1A may be a promising prognostic biomarker and therapeutic target in HCC.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.PubMedCrossRef

Chen WQ, Zheng RS, Zhang SW. Liver cancer incidence and mortality in China, 2009. Chin J Cancer. 2013;32(4):162–9. doi:10.5732/cjc.013.10027.PubMedCentralPubMedCrossRef

Li XP, Cao GW, Sun Q, Yang C, Yan B, Zhang MY, et al. Cancer incidence and patient survival rates among residents in the Pudong New Area of Shanghai between 2002 and 2006. Chin J Cancer. 2012. doi:10.5732/cjc.012.10200.

Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5–S16.PubMedCrossRef

Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9(4):416–23. doi:10.1038/nm843.PubMedCrossRef

Zhang CZ, Cao Y, Yun JP, Chen GG, Lai PB. Increased expression of ZBP-89 and its prognostic significance in hepatocellular carcinoma. Histopathology. 2012;60(7):1114–24. doi:10.1111/j.1365-2559.2011.04136.x.PubMedCrossRef

Yun JP, Miao J, Chen GG, Tian QH, Zhang CQ, Xiang J, et al. Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. Br J Cancer. 2007;96(3):477–84. doi:10.1038/sj.bjc.6603574.PubMedCentralPubMedCrossRef

Geli J, Kogner P, Lanner F, Natalishvili N, Juhlin C, Kiss N, et al. Assessment of NORE1A as a putative tumor suppressor in human neuroblastoma. Int J Cancer. 2008;123(2):389–94. doi:10.1002/ijc.23533.PubMedCrossRef

van der Weyden L, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta. 2007;1776(1):58–85. doi:10.1016/j.bbcan.2007.06.003.PubMedCentralPubMed

10.

Foukakis T, Au AY, Wallin G, Geli J, Forsberg L, Clifton-Bligh R, et al. The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion. J Clin Endocrinol Metab. 2006;91(3):1143–9. doi:10.1210/jc.2005-1372.PubMedCrossRef

11.

Vavvas D, Li X, Avruch J, Zhang XF. Identification of Nore1 as a potential Ras effector. J Biol Chem. 1998;273(10):5439–42.PubMedCrossRef

12.

Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene. 2002;21(9):1381–90. doi:10.1038/sj.onc.1205192.PubMedCrossRef

13.

Moshnikova A, Kuznetsov S, Khokhlatchev AV. Interaction of the growth and tumour suppressor NORE1A with microtubules is not required for its growth-suppressive function. BMC Res Notes. 2008;1:13. doi:10.1186/1756-0500-1-13.PubMedCentralPubMedCrossRef

14.

Shinmura K, Tao H, Nagura K, Goto M, Matsuura S, Mochizuki T, et al. Suppression of hydroxyurea-induced centrosome amplification by NORE1A and down-regulation of NORE1A mRNA expression in non-small cell lung carcinoma. Lung Cancer. 2011;71(1):19–27. doi:10.1016/j.lungcan.2010.04.006.PubMedCrossRef

15.

Hesson L, Dallol A, Minna JD, Maher ER, Latif F. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene. 2003;22(6):947–54. doi:10.1038/sj.onc.1206191.PubMedCrossRef

16.

Irimia M, Fraga MF, Sanchez-Cespedes M, Esteller M. CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer. Oncogene. 2004;23(53):8695–9. doi:10.1038/sj.onc.1207914.PubMedCrossRef

17.

Lorente A, Mueller W, Urdangarin E, Lazcoz P, Lass U, von Deimling A, et al. RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol. 2009;19(2):279–92. doi:10.1111/j.1750-3639.2008.00185.x.PubMedCrossRef

18.

Calvisi DF, Donninger H, Vos MD, Birrer MJ, Gordon L, Leaner V, et al. NORE1A tumor suppressor candidate modulates p21CIP1 via p53. Cancer Res. 2009;69(11):4629–37. doi:10.1158/0008-5472.CAN-08-3672.PubMedCrossRef

19.

Park SJ, Lee D, Choi CY, Ryu SY. Induction of apoptosis by NORE1A in a manner dependent on its nuclear export. Biochem Biophys Res Commun. 2008;368(1):56–61. doi:10.1016/j.bbrc.2008.01.044.PubMedCrossRef

20.

Park J, Kang SI, Lee SY, Zhang XF, Kim MS, Beers LF, et al. Tumor suppressor ras association domain family 5 (RASSF5/NORE1) mediates death receptor ligand-induced apoptosis. J Biol Chem. 2010;285(45):35029–38. doi:10.1074/jbc.M110.165506.PubMedCentralPubMedCrossRef

21.

Zhang CZ, Zhang H, Yun J, Chen GG, Lai PB. Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol. 2012;83(9):1278–89. doi:10.1016/j.bcp.2012.02.002.PubMedCrossRef

22.

Tommasi S, Dammann R, Jin SG, Zhang XF, Avruch J, Pfeifer GP. RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene. 2002;21(17):2713–20. doi:10.1038/sj.onc.1205365.PubMedCrossRef

23.

Lee CK, Lee JH, Lee MG, Jeong SI, Ha TK, Kang MJ, et al. Epigenetic inactivation of the NORE1 gene correlates with malignant progression of colorectal tumors. BMC Cancer. 2010;10:577. doi:10.1186/1471-2407-10-577.PubMedCentralPubMedCrossRef

24.

Nakamura N, Carney JA, Jin L, Kajita S, Pallares J, Zhang H, et al. RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest. 2005;85(9):1065–75. doi:10.1038/labinvest.3700306.PubMedCrossRef

25.

Macheiner D, Heller G, Kappel S, Bichler C, Stattner S, Ziegler B, et al. NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. J Hepatol. 2006;45(1):81–9. doi:10.1016/j.jhep.2005.12.017.PubMedCrossRef

26.

Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009;51(4):725–33. doi:10.1016/j.jhep.2009.03.028.PubMedCentralPubMedCrossRef

27.

Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006;130(4):1117–28. doi:10.1053/j.gastro.2006.01.006.PubMedCrossRef

28.

Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13(8):817–26. doi:10.1016/S1470-2045(12)70233-4.PubMedCrossRef

29.

Zhang CZ, Liu L, Cai M, Pan Y, Fu J, Cao Y, et al. Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS One. 2012;7(12):e51703. doi:10.1371/journal.pone.0051703.PubMedCentralPubMedCrossRef

30.

Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology. 2012;56(6):2242–54. doi:10.1002/hep.25907.PubMedCrossRef

31.

Huang XY, Ke AW, Shi GM, Zhang X, Zhang C, Shi YH, et al. alphaB-Crystallin complexes with 14-3-3zeta to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma. Hepatology. 2013. doi:10.1002/hep.26255.

32.

Blivet-Van Eggelpoel MJ, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, Rey C, et al. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol. 2012;57(1):108–15. doi:10.1016/j.jhep.2012.02.019.PubMedCrossRef

33.

Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 2009;16(5):425–38. doi:10.1016/j.ccr.2009.09.026.PubMedCentralPubMedCrossRef

34.

Fujimaki S, Matsuda Y, Wakai T, Sanpei A, Kubota M, Takamura M, et al. Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. Cancer Lett. 2012;319(1):98–108. doi:10.1016/j.canlet.2011.12.043.PubMedCrossRef

35.

Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol. 2010;52(1):88–95. doi:10.1016/j.jhep.2009.10.011.PubMedCrossRef

Title: NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis
Authors: Li-Li Liu
Mei-Fang Zhang
Ying-Hua Pan
Jing-Ping Yun
Chris Zhiyi Zhang
Publication date: 01-03-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 3/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1184-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

RETRACTED ARTICLE: The apoptotic effect of shikonin on human papillary thyroid carcinoma cells through mitochondrial pathway

Level of plasmacytoid dendritic cells is increased in non-small cell lung carcinoma

Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study

Role of EGFR as a prognostic factor for survival in head and neck cancer: a meta-analysis

Lack of association of microvessel density with prognosis of renal cell carcinoma: evidence from meta-analysis

Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer